Editas Medicine Inc
NASDAQ:EDIT 4:00:00 PM EDT
| Market Cap (Intraday) | 439.93M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.79 |
| 50-Day MA | $7.63 |
| 200-Day MA | $8.35 |
Editas Medicine Inc Stock, NASDAQ:EDIT
11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.401.9000
Number of Employees: 265
Description
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.